Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report report published on Friday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Eagle Pharmaceuticals stock opened at $0.98 on Friday. The stock’s 50 day moving average price is $0.68 and its 200 day moving average price is $2.35. Eagle Pharmaceuticals has a one year low of $0.00 and a one year high of $6.81.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. DGS Capital Management LLC raised its position in shares of Eagle Pharmaceuticals by 44.9% during the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares during the last quarter. Jane Street Group LLC acquired a new position in Eagle Pharmaceuticals during the 3rd quarter valued at about $96,000. RBF Capital LLC boosted its stake in Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 14,991 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Eagle Pharmaceuticals during the 3rd quarter worth about $453,000. Finally, Creative Planning bought a new stake in Eagle Pharmaceuticals in the third quarter valued at approximately $59,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.